Search Results
The prognostic value of IgHV mutational status with continuous vs time-limited therapy in CLL
Choosing between continuous and time-limited therapy in patients with high-risk CLL
The impact of IGHV mutational status in treatment decisions in CLL
The prognostic impact of TP53 and IgHV status in the era of targeted therapies in CLL
CLL: IgHV mutational status
Testing for IgHV and TP53 mutations to guide treatment decisions in CLL
The impact of MRD & genetics on outcomes to time-limited combinations in patients with CLL
The importance of TP53 & IGHV testing before treatment initiation in CLL
Defining high-risk CLL: known and emerging mutations
An insight into time-limited therapy in CLL
IGHV-Mutated vs IGHV-Unmutated CLL | What’s the Difference?
IgVH and Other High-Risk Cytogenetic Risk Factors in CLL
